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Abstract
Radionecrosis (RN) of brain tissue is a seri-
ous late complication of brain irradiation and
historically has been treated with corticos-
teroid therapy and alternatively surgical
decompression. Recently, bevacizumab has
been suggested for treatment of cerebral radi-
ation necrosis. We present a case of a 73-
years-old women affected by a primary non-
small cell lung cancer with a single brain
metastasis treated with radiosurgery. Two
years after radiosurgery the patient referred
neurological symptoms and a brain magnetic
resonance confirmed the presence of RN. The
patient refused surgical decompression so
underwent at the treatment with bevacizumab
7.5 mg/kg/2 weeks for a total of 4 cycles. After
two months of treatment the patient reported
strumental and clinical improvement. Ten
months after bevacizumab discontinuation the
patient experienced a recurrence of RN with
evident clinical manifestation and confirmed
by radiological imaging. A new treatment with
bevacizumab was not performed due to the
systemic progression disease and the worsen-
ing of clinical status. Despite limited to only
one clinical case, our study suggests the effica-
cy of bevacizumab to treat RN. Future studies
are needed to confirm its mechanism and to
properly define the optimal scheduling, dosage
and duration of therapy. 
Introduction
Radionecrosis (RN) is the most severe toxi-
city of radiosurgery (SRS) or stereotactic
radiotherapy (SRT) of brain metastases, usu-
ally occurring three or more months after com-
pletion of therapy. The symptoms range from
focal to generalized neurologic deficits with
loss of patient autonomy and negative impact
on the quality of life.1 The total radiation dose
and volume as well as fractionation regimen
are recognized as the main predictive factors
of this severe sequela.2-5
The pathogenesis is associated to endothe-
lial cell dysfunction with an increased release
of vascular endothelial growth factor (VEGF)
and a subsequent serious damage of the blood-
brain barrier. Deregulation of VEGF levels
causes vascular permeability, brain edema,
neuronal demyelination and finally necrosis.6-8
Despite the difficulty to discriminate
between tumor recurrence and radiation-
induced tissue damage, magnetic resonance
(MR) imaging is considered the gold standard
for the diagnosis of RN showing a contrast-
enhancing mass with brain white matter
changes and an edema within or adjacent to
the site of the original.9-11
Historically, the RN has always been treated
with corticosteroid therapy with poor results
and many side effects such as behavioral
changes, altered sleep patterns and changes in
appetite. Alternatively, the surgical decompres-
sion of necrotic area can provide a beneficial
palliative effect despite the radical removal of
the whole necrotic process is difficult to obtain
in most cases.10,12
Recently, bevacizumab (a humanized
murine monoclonal antibody against VEGF)
has been suggested as a new treatment modal-
ity for brain RN.11,13-22
Here, we report a case of a patient affected
by a post-SRS brain necrosis, who experienced
a prolonged clinical benefit from several cycles
of therapy with bevacizumab. 
Case Report
A 73-year-old women, affected by a non
small cell lung cancer (histological type: ade-
nocarcinoma) with a solitary brain metastasis
at diagnosis, was referred to our institution
hospital in August 2010 for a stereotactic treat-
ment. The staging exams [thorax-abdomen
computed tomography (CT) and whole body
PET/CT] excluded other distant metastases at
lung, liver and bone whereas a MR of brain
confirmed the presence of an asymptomatic
16×14 mm lesion located at the frontal subcor-
tical left gyrus. First surgical removal of lesion
was proposed, since the unique localization,
but the patient refused so was candidate to a
SRS. The radiation treatment was performed
using a dedicated Linear Accelerator
(TrueBeam Stx, Varian Medical System, PA,
USA), X6MV photon beam and a volumetric
modulated arc therapy (VMAT) technique was
used.
A total dose of 30 Gy in a single fraction was
prescribed to the isocenter with a target cov-
ered of 90% isodose line, as described by the
Fukuoka et al.12
Next, the patient underwent to 5 cycles of
cisplatin + pemetrexed with a partial response
followed by a radiation treatment of the pri-
mary tumor and involved nodes. Then, she
continued medical therapy with erlotinib for
three months.
Two years after SRS treatment the patient
reported neurological disorders such as cogni-
tive slowing and loss of memory.
As shown in Figure 1, a MR of the brain
detected presence of a well defined RN area
corresponding to previously SRS-treated
region. Specifically, the FSE T2 weighted
images (Figure 1a) showed a hypointense
lesion with irregular borders surrounded by
evident vasogenic edema whereas the diffu-
sion and post contrast SE T1 weighted images
revealed a central necrotic core and a periph-
eral enhancing component with restricted dif-
fusion. Moreover, the spectroscopic analysis
showed a reduction of normal peaks and an
abnormal increase of lipids (arrow) and lactate
(arrowhead). At first we started medical thera-
py with Dexamethasone at a dose of 8 mg twice
daily, however no improvements of neurologi-
cal symptoms were observed. Then, surgical
decompression was suggested but the patient
refused it. Thus, after obtained written
informed consent, we started medical therapy
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with bevacizumab 7.5 mg/Kg/2 weeks for a
total  of 4 cycles with clinical remission of neu-
rological symptoms. Moreover, 2 months after
the end of bevacizumab treatment, MR indicat-
ed significant reduction of RN area as shown
in Figure 2.
The axial FSE T2 weighted images (Figure
2a), the diffusion weighted images (Figure 2b)
and the SE T1 weighted images revealed the
reduction of the RN lesion together with the
perilesional edema whereas the subsequent
spectroscopic analysis showed the recovery of
normal peaks and the disappearance of lipids
and lactate (Figure 2).
The clinical and radiological remission
remained stable for an overall 8 months after
the end of Bevacizumab
Next, a subsequent MR at 10 months after
discontinuation of Bevacizumab showed a
recurrence of RN area together with the reap-
pearance of abnormal peaks typical of necrosis
(Figure 3). 
Due to the systemic progression disease and
the worsening of clinical status, the medical
therapy with Bevacizumab was definitely dis-
continued.
Discussion
RN of brain tissue is a possible late compli-
cation occurring after SRS of brain metas-
tases, usually diagnosed both at follow-up
imaging or at the appearance of neurological
symptoms. 
Common symptoms include psychomotor
slowing, seizures, generalized signs with loss
of patient autonomy and negative impact on
the life quality.1-5
In this paper, we report the case of a patient
who refused surgical removal and underwent
both to a clinical and radiological remission of
RN lesion after four cycles with low dose of
bevacizumab.
Despite poor data in literature, bevacizumab
treatment seems to be clinical beneficial for
patients affected by post radiation necrosis
lesions.11,13-22
Gonzalez et al.13 retrospectively reported sig-
nificant reduction of neurological symptoms
and radiological partial remission in 8 patients
using bevacizumab at the dose of 5 mg/kg/2
weeks or 7.5 mg/kg/3 weeks.
Torcuator et al.14 demonstrated radiographic
response in 6 patients with biopsy proven RN
treated with low doses of bevacizumab. All
patients had an average reduction of 79% for
the post gadolinium studies and 49% for the
FLAIR images. 
Moreover, Wang et al.17 reported that beva-
cizumab administered at the dose of 7.5
mg/kg/2 weeks was effective in reduction of
cerebral edema at RMI evaluation with a sub-
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Figure 1. Magnetic resonance before treatment with bevacizumab. The axial FSE T2
weighted image (a) revealed a hypointense lesion with irregular borders surrounded by
evident vasogenic edema. The diffusion weighted (b) and post contrast SE T1 weighted
(c) axial images allowed to distinguish a central core with necrotic behavior and an
enhancing peripheral component with restricted diffusion. The proton MRS (d) showed
a reduction of normal peaks, and an abnormal accumulation of lipids (arrow) and lactate
(arrowhead).
Figure 2. Magnetic resonance imaging two months after treatment with bevacizumab.
The axial FSE T2 weighted (a), diffusion weighted (b) and SE T1 weighted (c) axial
images revealed a reduction of the lesion and reactive edema. The MRS (d) showed a
recovery of the normal peaks and the disappearance of lipids and lactat. The Magnetic
Resonance imaging remained stable for other six months after treatment.
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sequent improvement of clinical symptoms in
17 patients affected by a symptomatic brain
RN.
Also Levin et al.,18 in 14 patients with biopsy
proven RN, reported the efficacy of bevacizum-
ab at the dose of 7.5 mg/kg/3 weeks to both
reduce the necrotic area and improve clinical
symptoms. 
Furthermore, similar results were reported
by Boothe et al.19 and Furuse et al.20,21 in their
retrospective studies. 
Finally, Tye et al.22 reviewed 16 different
studies for a total of 71 brain RN patients treat-
ed with.
The authors report that the median time of
starting treatment with Bevacizumab was 11
months by the end of radiotherapy and the
most frequently used scheduling was 7.5
mg/kg/2 weeks for a total of 4 cycles. In these
studies was observed a median decrease of
63% of contrast enhancement rate in T1
images and of 59% of signal abnormality in
T2/FLAIR, when compared pre-treatment and
post treatment images.
Overall, based on the current available data,
low doses of bevacizumab seem to be effica-
cious in reducing RN in patients affected by
brain metastases undergone to SRS or SRT,
apparently without any risk of clinical compli-
cation. 
Currently, the optimal scheduling and treat-
ment duration has not been yet established. 
Nevertheless, a significant amount of recur-
rence has been described several months after
bevacizumab discontinuation, indicating
repeated cycles might be warranted in absence
of contraindications. 
Conclusions
Bevacizumab seem to be very promising
agent for the treatment of brain RN as well as
anti-cancer drug. Our experience, despite limit-
ed to a case patient, supports the current avail-
able literature. Future studies are required to
properly evaluate the role of bevacizumab as an
efficacious agent against post radiation necro-
sis as well as to define the optimal scheduling,
dosage and duration of therapy. 
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Figure 3. Magnetic resonance imaging examination of the brain acquired 10 months after
discontinuation of treatment with bevacizumab. The axial FSE T2 weighted (a), diffusion
weighted (b) and SE T1 weighted (c) axial images demonstrated a recrudescence of the
radionecrotic phenomena with increased perilesional oedema and the MRS (d) allowed
to detect the reappearance of the abnormal peaks indicative of necrosis. 
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